Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Hosted on MSN
DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device
Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock. Hunterbrook said on Thursday that it has a short position on DXCM ...
Health and wellness platform FriskaAi announced an agreement with glucose monitoring specialist Dexcom to integrate data from Dexcom's G7 and G6 continuous glucose monitoring (CGM) systems into the ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback